DimAb® - Revolutionizing Monoclonal Antibody Development
DimAb® recombinant monoclonal antibody development platform represents a groundbreaking advancement in the realm of monoclonal antibody research and production. In contrast to traditional hybridoma-based approaches, DimAb® offers a range of distinctive advantages that are reshaping the field.
1. Direct IgG Gene Sequencing:
– DimAb® allows for the direct acquisition of IgG gene sequences from immunoreactive B cells.
– Eliminates the need for labor-intensive hybridoma fusion processes.
2. Abundance of Immunoreactive B Cell Clones:
– Our platform easily isolates over 1000 immunoreactive B cell clones from a single immunized animal.
– This extensive pool enhances the screening potential for monoclonal antibodies.
3. Enhanced Success Rate:
– DimAb® boasts a significantly higher success rate for downstream applications compared to traditional hybridoma platforms.
– Increased likelihood of identifying antibodies with exceptional specificity, sensitivity, and affinity.
4. Direct Editing and Optimization:
– With direct access to IgG genes, we can edit, optimize, and identify antibodies for various downstream applications.
– Enables processes like humanization of antibodies, affinity maturation, and cell line construction.
5. Species Flexibility:
– DimAb® is not bound by the availability of myeloma fusion partners.
– Offers the possibility of monoclonal antibody development from different animal species.
Custom Antibody Request Form
Unlocking New Possibilities:
With the DimAb® platform, we introduce a unique solution for antigens with high homology and weak immunogenicity. By employing various host species for immunization, DimAb® transcends limitations and opens doors to previously challenging targets.
DimAb® platform has been fine-tuned for the high-throughput development of recombinant monoclonal antibodies derived from rabbits and mice. At DIMA, we are committed to driving innovation, expanding possibilities, and delivering excellence in antibody development.
Comparison between DimAb® Platform and Hybridoma Platform
|Features||DimAb® mAb Platform||Hybridoma mAb Platform|
|Success Rate||High project success rate（80-90%）||Low project success rate（50%）|
|Storage mode||The antibody gene sequence is directly obtained for easy storage and transmission.||Hybridoma cell preservation is costly, demanding extensive liquid nitrogen and storage equipment.|
|Screening efficiency||Every antibody-secreting B cell can be screened and isolated in theory.||Fusion efficiency limits stable B cell clone formation.|
|Antibody quality||Recombinant antibody with DNA sequence available||Hybridoma cell instability risks gene loss.|
|Diverse animal mAbs||Obtain recombinant mAbs from various species.||Mouse mAbs widely available due to IP.|
|Preparation process||Rapid process, direct antibody gene retrieval.||Hybridoma antibodies are unstable; gene cloning required for cell line stability|
|Animal ethics||No need to kill animals||Need to sacrifice animal to obtain splenocytes|